U5P Stock Chart & Stats
€1.12
€0.01(0.89%)
At close: 4:00 PM EDT
€1.12
€0.01(0.89%)
Day’s Range― - ―
52-Week Range€0.74 - €1.60
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€98.89M
Enterprise Value€105.99M
Total Cash (Recent Filing)€19.89M
Total Debt (Recent Filing)€17.86M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
Nov 18, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding90,203,354
10 Day Avg. Volume40
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.88
Price to Sales (P/S)0.00
P/FCF Ratio-3.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.37Price Target Upside200.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.29
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Implantable Drug-delivery PlatformVivani’s NanoPortal implant approach targets a meaningful treatment problem: maintaining continuous medication delivery for chronic conditions. If clinical development succeeds, longer-duration dosing could improve adherence and differentiate the company from conventional injections or daily regimens.
Clinical Execution In Obesity ProgramCompleting SLIM-1 enrollment and dosing ahead of schedule demonstrates operational execution in the lead metabolic program. The resulting data is intended to support an Investigational New Drug filing and a Phase 2 dose-ranging study, creating defined development milestones.
External Validation From Novo NordiskA formal evaluation by Novo Nordisk provides external validation of NPM-139 and the NanoPortal platform from a major GLP-1 developer. Although not a commercialization agreement, the relationship may improve scientific credibility and support future strategic options.
Bears Say
No Commercial Revenue And Persistent LossesVivani has not yet generated revenue and continues to report substantial net losses, so its business remains dependent on successful clinical development rather than commercial operating performance. Without a visible revenue ramp, profitability and operating leverage remain distant.
Heavy And Sustained Cash BurnPersistent negative operating and free cash flow indicates that Vivani’s programs consume significant cash before producing commercial returns. Continued development spending will likely require the company to preserve funding access, making liquidity management central to execution over the coming quarters.
Meaningful Leverage Relative To EquityDebt that is nearly equal to shareholders’ equity reduces financial flexibility for a development-stage company already generating losses and burning cash. If additional funding is needed, existing leverage can increase financing pressure and constrain capital allocation while clinical programs advance.
Vivani Medical News
U5P FAQ
What was Vivani Medical’s price range in the past 12 months?
Vivani Medical lowest stock price was €0.73 and its highest was €1.60 in the past 12 months.
What is Vivani Medical’s market cap?
Vivani Medical’s market cap is €98.89M.
When is Vivani Medical’s upcoming earnings report date?
Vivani Medical’s upcoming earnings report date is Nov 18, 2026 which is in 43 days.
How were Vivani Medical’s earnings last quarter?
Vivani Medical released its earnings results on Aug 13, 2026. The company reported -€0.062 earnings per share for the quarter, beating the consensus estimate of -€0.074 by €0.012.
Is Vivani Medical overvalued?
According to Wall Street analysts Vivani Medical’s price is currently Undervalued.
Does Vivani Medical pay dividends?
Vivani Medical does not currently pay dividends.
What is Vivani Medical’s EPS estimate?
Vivani Medical’s EPS estimate is -0.07.
How many shares outstanding does Vivani Medical have?
Vivani Medical has 90,203,354 shares outstanding.
What happened to Vivani Medical’s price movement after its last earnings report?
Vivani Medical reported an EPS of -€0.062 in its last earnings report, beating expectations of -€0.074. Following the earnings report the stock price went down -1.835%.
Which hedge fund is a major shareholder of Vivani Medical?
Currently, no hedge funds are holding shares in DE:U5P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vivani Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
44.05%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Vivani Medical
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.
U5P Stock 12 Month Forecast
Average Price Target
€3.37
▲(200.49% Upside)